CTI BioPharma Statistics
Total Valuation
CTI BioPharma has a market cap or net worth of $1.20 billion. The enterprise value is $1.26 billion.
| Market Cap | 1.20B |
| Enterprise Value | 1.26B |
Important Dates
The last earnings date was Monday, August 7, 2023, after market close.
| Earnings Date | Aug 7, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
CTI BioPharma has 131.88 million shares outstanding. The number of shares has increased by 31.78% in one year.
| Shares Outstanding | 131.88M |
| Shares Change (YoY) | +31.78% |
| Shares Change (QoQ) | +2.32% |
| Owned by Insiders (%) | 5.50% |
| Owned by Institutions (%) | 83.29% |
| Float | 99.89M |
Valuation Ratios
The trailing PE ratio is -16.23 and the forward PE ratio is -47.81.
| PE Ratio | -16.23 |
| Forward PE | -47.81 |
| PS Ratio | 15.82 |
| Forward PS | 8.75 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27
| Current Ratio | 1.27 |
| Quick Ratio | 1.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -55.80% |
| Return on Capital (ROIC) | -44.80% |
| Revenue Per Employee | $596,606 |
| Profits Per Employee | -$545,189 |
| Employee Count | 127 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 10.15 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +61.17% in the last 52 weeks. The beta is 0.83, so CTI BioPharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.83 |
| 52-Week Price Change | +61.17% |
| 50-Day Moving Average | 7.53 |
| 200-Day Moving Average | 5.89 |
| Relative Strength Index (RSI) | 83.62 |
| Average Volume (30 Days) | 5,770,332 |
Short Selling Information
The latest short interest is 11.27 million, so 8.55% of the outstanding shares have been sold short.
| Short Interest | 11.27M |
| Short Previous Month | 8.08M |
| Short % of Shares Out | 8.55% |
| Short % of Float | 11.29% |
| Short Ratio (days to cover) | 1.08 |
Income Statement
In the last 12 months, CTI BioPharma had revenue of $75.77 million and -$69.24 million in losses. Loss per share was -$0.56.
| Revenue | 75.77M |
| Gross Profit | 71.31M |
| Operating Income | -53.93M |
| Pretax Income | -69.24M |
| Net Income | -69.24M |
| EBITDA | -51.83M |
| EBIT | -53.98M |
| Loss Per Share | -$0.56 |
Balance Sheet
The company has $59.01 million in cash and $116.46 million in debt, giving a net cash position of -$57.44 million or -$0.44 per share.
| Cash & Cash Equivalents | 59.01M |
| Total Debt | 116.46M |
| Net Cash | -57.44M |
| Net Cash Per Share | -$0.44 |
| Equity / Book Value | -25.35M |
| Book Value Per Share | -0.19 |
| Working Capital | 18.23M |
Cash Flow
| Operating Cash Flow | -82.32M |
| Capital Expenditures | n/a |
| Free Cash Flow | -82.32M |
| FCF Per Share | -$0.63 |
Margins
Gross margin is 94.11%, with operating and profit margins of -71.18% and -91.38%.
| Gross Margin | 94.11% |
| Operating Margin | -71.18% |
| Pretax Margin | -91.38% |
| Profit Margin | -91.38% |
| EBITDA Margin | -68.40% |
| EBIT Margin | -71.24% |
| FCF Margin | -108.64% |
Dividends & Yields
CTI BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.78% |
| Shareholder Yield | -31.78% |
| Earnings Yield | -5.78% |
| FCF Yield | -6.87% |
Analyst Forecast
The average price target for CTI BioPharma is $9.80, which is 7.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.80 |
| Price Target Difference | 7.81% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 59.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 3, 2017. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 3, 2017 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
CTI BioPharma has an Altman Z-Score of -27.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.07 |
| Piotroski F-Score | 3 |